News

Apr 2016 – Notice of allowance for issuance of patent “Novel Process for Synthesis of Polyphenols” by USPTO

Feb 2016 – XIV International Conference on Duchenne and Becker Muscular Dystrophy. “Mitochondria As A New Target For Drug Development In Muscular Dystrophy”. XIV International Conference on Duchenne and Becker Muscular Dystrophy.

Jan 2016 – Notice of allowance for issuance of patent “Novel Process for Synthesis of Polyphenols” by Japan PTO

Aug 2015 – Notice of allowance for issuance of patent “Flavanoid Compounds” by USPTO

June 2015 – 2015 PPMD Connect Conference. “Epicatechin: Targeting Bioenergetics As a Novel Therapeutic Approach to Muscular Dystrophy”. 2015 Parent Project Muscular Dystrophy Connect Conference. June 20, 2015″.

May 2015 – Funding from Broadview Ventures

Mar 2015 – 2015 Muscular Dystrophy Association Scientific Conference. “Epicatechin enhances mitochondrial biogenesis, increases dystrophin and utrophin, increases follistatin while decreasing myostatin, and improves skeletal muscle exercise response in adults with Becker muscular dystrophy”.

Mar 2015 – What is Epicatechin? Posted By Parent Project Muscular Dystrophy.

Jan 2015 – Closed Series B financing round

Sept 2014 – Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound.

May 2013 – Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound.

April 2013 – Closed Series A financing round.

Mar 2013 – Completed triglyceride trial with Cardero Therapeutics lead compound.

June 2012 – Financing from current investors and promoters of the company.

2012 – Initiated triglyceride trial with Cardero Therapeutics lead compound.